uPAR Antibody from R&D Systems, a Bio-Techne Brand

Yes, the uPAR antibody has been shown to be effective in studies investigating the role of uPAR in cancer progression. For instance, research has demonstrated that uPAR enhances the malignant potential of triple-negative breast cancer by interacting with uPA and IGF1R, indicating its significance in tumorigenesis and potential as a therapeutic target (Huber et al., 2016).

The uPAR antibody has been utilized in immunoprecipitation protocols to identify interaction partners of uPAR, confirming its suitability for such applications (Mekkawy et al., 2012; Huber et al., 2016).

The uPAR antibody has been effectively used in various assay formats, including Western blotting and immunocytochemistry, as evidenced by its application in studies measuring uPAR levels and interactions in different cell types (Abraham et al., 2021; Narayanaswamy et al., 2016).

The uPAR antibody is reactive with human, mouse, and rabbit species. It has been shown to detect human uPAR with less than 1% cross-reactivity with recombinant mouse uPAR in direct ELISAs, indicating a high level of specificity (R&D Systems).